Trial Profile
A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary) ; Risperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Janssen Research & Development
- 24 Dec 2021 This trial has been completed in Czech Republic, according to European Clinical Trials Database record.
- 22 Jul 2011 Results published in the International Journal of Neuropsychopharmacology.
- 18 May 2009 Results presented at the 162nd Annual Meeting of the American Psychiatric Association (APA 2009).